The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are ...

AstraZeneca shares tumbled nearly 10% in London after a late-stage trial for an experimental heart disease failed to meet its ...

The FDA expands approval of Skyrizi (risankizumab-rzaa) for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis.

Moderna said on Thursday it has secured a European Commission contract to ​supply its respiratory syncytial virus vaccine ‌to ...

The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...

Aseptic PFS production integrates validated mixing, 0.2 μm sterile filtration, Annex 1/USP-aligned controls, and CCI verification to support sterility assurance throughout shelf life.

The new presentation is expected to provide an additional self-administration option for patients with polycythemia vera.

The FDA has approved a prefilled injection device for adults with polycythemia vera, according to a press release. The ...

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval ...

AbbVie Inc. (NYSE:ABBV) will trade ex-dividend on July 15, putting it among the 10 Best July Dividend Stocks to Buy. On June ...

Hospital use drugs hitting shortage deadlines in July include six critical medications with FDA dates, impacting supply and patient care management.

Health Minister Dr Aaron Motsoaledi reveals the ongoing challenges of medicine stock disruptions in South Africa, detailing ...